StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30461% above fair value
$94.23−2.10 (-2.18%)

Close on Nov 16, 2026Market cap $14.81BP/E 72.5Yield –

Kiniksa Pharmaceuticals International EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Kiniksa Pharmaceuticals International's EV/EBITDA was 71.7× on Nov 11, 2026, against 73.3× a year earlier. Over the last 2 years it ranged from 22.1× to 432.7×, with a median of 49.4×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202671.7×+0.9
2025Dec 31, 202570.8×+48.7
2023Oct 31, 202322.1×–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?